Efficacy and safety of difamilast, a topical PDE4 inhibitor, in a phase 2 study of pediatric patients with atopic dermatitis

Background: Atopic dermatitis (AD) is a common chronic, relapsing inflammatory skin disorder associated with increased PDE4 activity, characterized by intense and persistent pruritus which can cause significant impairment in quality of life, including sleep disturbance. Difamilast, a PDE4 inhibitor which is highly selective for PDE4B, is being developed as a 1% ointment for the topical treatment of AD.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research